^Awada G, Neyns B (March 2022). "Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights". Current Opinion in Oncology. 34 (2): 115–122. doi:10.1097/CCO.0000000000000817. PMID 35050937.
^Kim TW, Lee J, Shin SJ, Kim JS, Kim YJ, Han HS, Lee SJ, Lim HS, Hong YH, Noh YS, Kyoung Y (31 May 2019). "Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study". Journal of Clinical Oncology. 37 (15 suppl): 3000. doi:10.1200/JCO.2019.37.15_suppl.3000.
belvarafenib, developed, hanmi, pharmaceuticals, genentech, small, molecule, dimer, type, inhibitor, which, shows, anti, tumor, clinical, activity, cancer, patients, with, brafv600e, nras, mutations, clinical, dataother, nameshm95573, gdc5573, rg6185routes, of. Belvarafenib developed by Hanmi Pharmaceuticals and Genentech is a small molecule RAF dimer type II inhibitor 1 which shows anti tumor clinical activity in cancer patients with BRAFV600E and NRAS mutations 2 BelvarafenibClinical dataOther namesHM95573 GDC5573 RG6185Routes ofadministrationBy mouthIdentifiersIUPAC name 4 amino N 1 3 chloro 2 fluoroanilino 6 methylisoquinolin 5 yl thieno 3 2 d pyrimidine 7 carboxamideCAS Number1446113 23 0PubChem CID89655386IUPHAR BPS11544ChemSpider64878400UNII31M3WLJ3KGChEMBLChEMBL3977543Chemical and physical dataFormulaC 23H 16Cl F N 6O SMolar mass478 93 g mol 13D model JSmol Interactive imageSMILES CC1 C C2 C C C1 C NC C2 NC3 C C CC C3 Cl F NC O C4 CSC5 C4N CN C5NInChI InChI InChI 1S C23H16ClFN6OS c1 11 5 6 13 12 7 8 27 22 13 30 16 4 2 3 15 24 17 16 25 18 11 31 23 32 14 9 33 20 19 14 28 10 29 21 20 26 h2 10H 1H3 H 27 30 H 31 32 H2 26 28 29 Key KVCQTKNUUQOELD UHFFFAOYSA NReferences Edit Awada G Neyns B March 2022 Melanoma with genetic alterations beyond the BRAFV600 mutation management and new insights Current Opinion in Oncology 34 2 115 122 doi 10 1097 CCO 0000000000000817 PMID 35050937 Kim TW Lee J Shin SJ Kim JS Kim YJ Han HS Lee SJ Lim HS Hong YH Noh YS Kyoung Y 31 May 2019 Belvarafenib a novel pan RAF inhibitor in solid tumor patients harboring BRAF KRAS or NRAS mutations Phase I study Journal of Clinical Oncology 37 15 suppl 3000 doi 10 1200 JCO 2019 37 15 suppl 3000 This antineoplastic or immunomodulatory drug article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Belvarafenib amp oldid 1136282381, wikipedia, wiki, book, books, library,